Ghosn Aya, Bassam Khalil, Al Zein Mohammad, Nasser Suzanne A, Pintus Gianfranco, Eid Ali H
Memorial Sloan Kettering, Newyork, NY, USA.
Cleveland Clinic, Cleveland, OH, USA.
Inflammopharmacology. 2025 Sep 15. doi: 10.1007/s10787-025-01925-5.
Colorectal cancer (CRC) is a significant global health challenge, ranking as the third most common cancer and the second leading cause of cancer-related deaths worldwide. Its development is influenced by several risk factors, including smoking, diets rich in red meat, and the effects of stress-related hormones such as epinephrine and norepinephrine. These hormones act through β-adrenergic receptors (β-ARs), which are present on CRC cells and are associated with cancer-promoting processes such as increased cell growth, invasion, blood vessel formation, and accelerated disease progression. Notably, β-ARs blockers have shown potential in slowing CRC progression, pointing to a promising therapeutic strategy. This review explores the main signaling pathways through which β-ARs contribute to cancer development and how various risk factors may influence these mechanisms. We also provide an overview of current preclinical and clinical studies on β-AR blockers in CRC, identify existing gaps in knowledge, and propose directions for future research to optimize therapeutic outcomes.
结直肠癌（CRC）是一项重大的全球健康挑战，在全球范围内是第三大常见癌症，也是癌症相关死亡的第二大主要原因。其发展受到多种风险因素的影响，包括吸烟、富含红肉的饮食以及肾上腺素和去甲肾上腺素等与压力相关激素的作用。这些激素通过β-肾上腺素能受体（β-ARs）发挥作用，β-ARs存在于CRC细胞上，并与促进癌症的过程相关，如细胞生长增加、侵袭、血管形成以及疾病进展加速。值得注意的是，β-ARs阻滞剂已显示出减缓CRC进展的潜力，这指向了一种有前景的治疗策略。本综述探讨了β-ARs促进癌症发展的主要信号通路，以及各种风险因素可能如何影响这些机制。我们还概述了目前关于CRC中β-AR阻滞剂的临床前和临床研究，确定了现有知识空白，并提出了未来研究的方向，以优化治疗效果。
